Comparative Pharmacology
Head-to-head clinical analysis: CIDOFOVIR versus SYLATRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIDOFOVIR versus SYLATRON.
CIDOFOVIR vs SYLATRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cidofovir is a nucleotide analog that inhibits viral DNA polymerase by competing with deoxycytidine triphosphate for incorporation into viral DNA, resulting in chain termination and inhibition of viral replication.
Peginterferon alfa-2b binds to type I interferon receptors, activating JAK-STAT signaling and inducing expression of antiviral, antiproliferative, and immunomodulatory proteins.
5 mg/kg intravenously once weekly for 2 weeks, then 5 mg/kg every 2 weeks. Administer with probenecid 2 g orally 3 hours before dose, then 1 g at 2 and 8 hours after dose. Hydrate with 1 L normal saline before infusion.
200 mcg/kg subcutaneously once weekly for 1 year in combination with oral ribavirin.
None Documented
None Documented
Clinical Note
moderateCidofovir + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cidofovir."
Clinical Note
moderateTenofovir disoproxil + Cidofovir
"Tenofovir disoproxil may decrease the excretion rate of Cidofovir which could result in a higher serum level."
Terminal elimination half-life is approximately 2.5 hours. However, the intracellular half-life of the active diphosphate metabolite is >48 hours, supporting once-weekly dosing.
Terminal elimination half-life is approximately 40 hours (range 27-60 hours) following subcutaneous administration. This prolonged half-life supports once-weekly dosing.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for approximately 90% of the administered dose. Biliary/fecal elimination is minimal (<5%).
Renal clearance is the primary route of elimination for peginterferon alfa-2b. Approximately 30% of the dose is excreted unchanged in urine, with the remainder metabolized and excreted via bile/feces.
Category D/X
Category C
Antiviral
Interferon Antineoplastic/Antiviral